762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors

• Bin Zhang,
• Gregory Cote,
• Marsha Crochiere,
• Anthony W Tolcher,
• Shui He,
• Jason Henry,
• Alexander I Spira,
• Shiraj Sen,
• Judy S Wang,
• Sharon Wilks,
• Benedito Carneiro,
• Frank Yung-Chin Tsai,
• Sondra Smyrnios,
• Dipali Unadkat

Affiliations

Bin Zhang

Beckman Research Institute at City of Hope, Duarte, CA, USA

Gregory Cote

Department of Gastroenterology, Oregon Health Sciences University, Portland, Oregon, USA

Marsha Crochiere

13Vigeo Therapeutics, Cambridge, MA, USA

Anthony W Tolcher

13NEXT Oncology, San Antonio, TX, USA

Shui He

19Replimune, Woburn, USA

Jason Henry

1Sarah Cannon Research Institute, Denver, CO, USA

Alexander I Spira

2Next Oncology, Fairfax, VA, USA

Shiraj Sen

1NEXT Oncology, Irving, TX, USA

Judy S Wang

9Florida Cancer Specialists/SCRI, Sarasota, FL, USA

Sharon Wilks

1NEXT Oncology, San Antonio, TX, USA

Benedito Carneiro

2Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Frank Yung-Chin Tsai

7HonorHealth, Scottsdale, AZ, USA

Sondra Smyrnios

9Pyxis Oncology, Boston, MA, USA

Dipali Unadkat

9Pyxis Oncology, Boston, MA, USA